Fluoropyrimidine (FP) + bevacizumab (BEV) + atezolizumab vs FP/BEV in BRAFwt metastatic colorectal cancer (mCRC): Findings from Cohort 2 of MODUL – a multicentre, randomized trial of biomarker-driven maintenance treatment following first-line induction therapy
Axel Grothey(Campbell Clinic), Hans‐Joachim Schmoll(Martin Luther University Halle-Wittenberg), Josep Tabernero(Deaconess Hospital), Frank Gilberg(Roche (Switzerland)), Peter J. O’Dwyer(University of Pennsylvania), Jordan Winter(Roche (Switzerland)), Christoph Mancao(Roche (Switzerland)), Aimery de Gramont(Institut Hospitalier Franco Britannique), Ivan Bosanac(Roche (Switzerland)), Michel Ducreux(Université Paris-Saclay), Eric Van Cutsem(Universitair Ziekenhuis Leuven), Dirk Arnold(Asklepios Klinik Altona), Stefanie Srock(Roche (Switzerland))
Cited by 103
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k